[1]
|
Siegel, R.L., Miller, K.D., Fuchs, H.E., et al. (2022) Cancer Statistics, 2022. CA: A Cancer Journal for Clinicians, 72, 7-33. https://doi.org/10.3322/caac.21708
|
[2]
|
Cao, W., Chen, H.-D., Yu, Y.-W., et al. (2021) Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics 2020. Chinese Medical Journal, 134, 783-791.
https://doi.org/10.1097/CM9.0000000000001474
|
[3]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Can-cer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[4]
|
Herbst, R.S., Morgensztern, D. and Boshoff, C. (2018) The Biology and Management of Non-Small Cell Lung Cancer. Nature, 553, 446-454. https://doi.org/10.1038/nature25183
|
[5]
|
Barta, J.A., Powell, C.A. and Wisnivesky, J.P. (2019) Global Epidemi-ology of Lung Cancer. Annals of Global Health, 85, Article No. 8. https://doi.org/10.5334/aogh.2419
|
[6]
|
Woodard, G.A., Jones, K.D. and Jablons, D.M. (2016) Lung Cancer Stag-ing and Prognosis. Cancer Research and Treatment, 170, 47-75. https://doi.org/10.1007/978-3-319-40389-2_3
|
[7]
|
Pennell, N.A., Neal, J.W., Chaft, J.E., et al. (2019) SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients with Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 37, 97-104. https://doi.org/10.1200/JCO.18.00131
|
[8]
|
Tong, M., Gao, M., Xu, Y., et al. (2019) SHR-A1403, a Novel c-Mesenchymal-Epithelial Transition Factor (c-Met) Antibody-Drug Conjugate, Overcomes AZD 9291 Resistance in Non-Small Cell Lung Cancer Cells Overexpressing c-Met. Cancer Sci-ence, 110, 3584-3594. https://doi.org/10.1111/cas.14180
|
[9]
|
张振中, 吕俊杰. 脂质体紫杉醇联合奈达铂治疗对NSCLC血清miR-4731-3p与miR-21的影响及意义[J]. 中南医学科学杂志, 2019, 47(6): 589-592.
|
[10]
|
Teixidó, C., Vilariño, N., Reyes, R., et al. (2018) PD-L1 Expression Testing in Non-Small Cell Lung Cancer. Therapeutic Ad-vances in Medical Oncology, 10. https://doi.org/10.1177/1758835918763493
|
[11]
|
Wang, F., Xia, T., Li, Z., et al. (2023) Current Status of Clinical Trial Research and Application of Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer. Frontiers in Oncology, 13, Article ID: 1213297.
https://doi.org/10.3389/fonc.2023.1213297
|
[12]
|
Abaza, A., Sid Idris, F., Anis Shaikh, H., et al. (2023) Pro-grammed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics. Cureus, 15, e44582.
https://doi.org/10.7759/cureus.44582
|
[13]
|
Chen, P., Liu, Y., Wen, Y., et al. (2022) Non-Small Cell Lung Cancer in China. Cancer Communications, 42, 937-970.
https://doi.org/10.1002/cac2.12359
|
[14]
|
Tostes, K., Siqueira, A.P., Reis, R.M., et al. (2023) Biomarkers for Im-mune Checkpoint Inhibitor Response in NSCLC: Current Developments and Applicability. International Journal of Mo-lecular Sciences, 24, Article ID: 11887.
https://doi.org/10.3390/ijms241511887
|
[15]
|
马海玥, 贾佳, 郭会芹, 等. 肺腺癌胸水标本中PD-L1的蛋白表达与临床病理特征及分子改变的相关性研究[J]. 中国肺癌杂志, 2020, 23(3): 150-155.
|
[16]
|
Ohaegbulam, K.C., Assal, A., Lazar-Molnar, E., et al. (2015) Human Cancer Immunotherapy with Antibodies to the PD-1 and PD-L1 Path-way. Trends in Molecular Medicine, 21, 24-33. https://doi.org/10.1016/j.molmed.2014.10.009
|
[17]
|
杨德松. PD-1/PD-L1在非小细胞肺癌中的临床研究进展[J]. 中国肿瘤临床, 2017, 44(14): 726-730.
|
[18]
|
Pezzuto, A., Cap-puzzo, F., D’Arcangelo, M., et al. (2020) Prognostic Value of p16 Protein in Patients with Surgically Treated Non-small Cell Lung Cancer, Relationship with Ki-67 and PD-L1. Anticancer Research, 40, 983-990.
https://doi.org/10.21873/anticanres.14032
|
[19]
|
Parakh, S., Ernst, M. and Poh, A.R. (2021) Multicellular Effects of STAT3 in Non-Small Cell Lung Cancer: Mechanistic Insights and Therapeutic Opportunities. Cancers, 13, Article No. 6228. https://doi.org/10.3390/cancers13246228
|
[20]
|
Zhang, H., Dai, Z., Wu, W., et al. (2021) Regulatory Mecha-nisms of Immune Checkpoints PD-L1 and CTLA-4 in Cancer. Journal of Experimental & Clinical Cancer Research, 40, Article No. 184.
https://doi.org/10.1186/s13046-021-01987-7
|
[21]
|
Asgarova, A., Asgarov, K., Godet, Y., et al. (2018) PD-L1 Ex-pression Is Regulated by Both DNA Methylation and NF-κB during EMT Signaling in Non-Small Cell Lung Carcinoma. OncoImmunology, 7, e1423170.
https://doi.org/10.1080/2162402X.2017.1423170
|
[22]
|
D’Incecco, A., Andreozzi, M., Ludovini, V., et al. (2015) PD-1 and PD-L1 Expression in Molecularly Selected Non- Small-Cell Lung Cancer Patients. British Journal of Cancer, 112, 95-102. https://doi.org/10.1038/bjc.2014.555
|
[23]
|
伍锦凤, 何杰. 非小细胞肺癌中EGFR、ALK、ROS1基因突变和PD-L1表达及临床意义[J]. 临床与实验病理学杂志, 2022, 38(9): 1133-1136.
|
[24]
|
周彩存, 王洁, 王宝成, 等. 中国非小细胞肺癌免疫检查点抑制剂治疗专家共识(2020年版) [J]. 中国肺癌杂志, 2021, 24(4): 217-235.
|
[25]
|
Garon, E.B., Rizvi, N.A., Hui, R., et al. (2015) Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. New England Journal of Medicine, 372, 2018-2028. https://doi.org/10.1056/NEJMoa1501824
|
[26]
|
Borghaei, H., Paz-Ares, L., Horn, L., et al. (2015) Nivolumab ver-sus Docetaxel in Advanced Nonsquamous Non- Small-Cell Lung Cancer. New England Journal of Medicine, 373, 1627-1639.
https://doi.org/10.1056/NEJMoa1507643
|
[27]
|
Perrotta, F., Rocco, D., Vitiello, F., et al. (2019) Immune Check-point Blockade for Advanced NSCLC: A New Landscape for Elderly Patients. International Journal of Molecular Sci-ences, 20, Article No. 2258.
https://doi.org/10.3390/ijms20092258
|
[28]
|
Zhao, Y., Shi, F., Zhou, Q., et al. (2020) Prognostic Significance of PD-L1 in Advanced Non-Small Cell Lung Carcinoma. Medicine, 99, e23172. https://doi.org/10.1097/MD.0000000000023172
|
[29]
|
Kanitkar, A., Schwartz, A., George, J., et al. (2018) Causes of Death in Long-Term Survivors of Non-Small Cell Lung Cancer: A Regional Surveillance, Epidemiology, and End Results Study. Annals of Thoracic Medicine, 13, Article No. 76. https://doi.org/10.4103/atm.ATM_243_17
|
[30]
|
Dantoing, E., Piton, N., Salaün, M., et al. (2021) Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations. International Journal of Molecular Sciences, 22, Article No. 6288.
https://doi.org/10.3390/ijms22126288
|
[31]
|
Olivares-Hernández, A., González del Portillo, E., Tamayo-Velasco, Á., et al. (2023) Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: From Current Perspectives to Future Treat-ments—A Systematic Review. Annals of Translational Medicine, 11, 354-354. https://doi.org/10.21037/atm-22-4218
|
[32]
|
Moya-Horno, I., Viteri, S., Karachaliou, N., et al. (2018) Combination of Immunotherapy with Targeted Therapies in Advanced Non-Small Cell Lung Cancer (NSCLC). Therapeutic Advances in Medical Oncology, 10.
https://doi.org/10.1177/1758834017745012
|
[33]
|
Malhotra, J., Jabbour, S.K. and Aisner, J. (2017) Current State of Immunotherapy for Non-Small Cell Lung Cancer. Translational Lung Cancer Research, 6, 196-211. https://doi.org/10.21037/tlcr.2017.03.01
|
[34]
|
Teng, M.W.L., Ngiow, S.F., Ribas, A., et al. (2015) Classifying Cancers Based on T-Cell Infiltration and PD-L1. Cancer Research, 75, 2139-2145. https://doi.org/10.1158/0008-5472.CAN-15-0255
|